Hims & Hers Health, Inc. HIMS
HIMS among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
HIMS and 9 peers, year by year
The 9 Health care companies closest to HIMS in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Gross margin | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|
| HIMS Hims & Hers Health, Inc. | FY2025 | $2.3B | +59.0% | 73.8% | 4.5% | 5.5% | 2.4% | 23.7% | - |
| NVST Envista Holdings Corp | FY2025 | $2.7B | +8.3% | 54.7% | 7.9% | 1.7% | 8.5% | 1.5% | 0.47 |
| MEDP Medpace Holdings, Inc. | FY2025 | $2.5B | +20.0% | - | 21.1% | 17.8% | 26.9% | 98.3% | - |
| NTRA Natera, Inc. | FY2025 | $2.3B | +35.9% | - | −13.4% | −9.0% | 4.7% | −12.2% | 0.05 |
| RVTY Revvity | FY2025 | $2.9B | +3.7% | - | 12.5% | 8.4% | 17.8% | 3.3% | 0.44 |
| BKD Brookdale Senior Living Inc. | FY2025 | $3.2B | +2.2% | 26.2% | 0.4% | −8.2% | 0.5% | n/m | n/m |
| CHE Chemed Corp | FY2025 | $2.5B | +4.1% | - | 13.4% | 10.5% | 12.9% | 27.1% | - |
| RPRX Royalty Pharma plc | FY2025 | $2.4B | +5.1% | - | 65.6% | 32.4% | - | 7.9% | 0.92 |
| GMED Globus Medical Inc | FY2025 | $2.9B | +16.7% | - | 16.3% | 18.3% | 20.0% | 11.8% | - |
| QDEL QuidelOrtho Corp | FY2025 | $2.7B | −1.9% | - | −33.7% | −41.5% | −3.0% | −58.9% | 1.40 |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2019 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2019 to FY2025
Revenue as reported in the 10-K.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| HIMS Dec | $82.6M | $148.8M | $271.9M | $526.9M | $872.0M | $1.5B | $2.3B |
| NVST Dec | $2.3B | $1.9B | $2.5B | $2.6B | $2.6B | $2.5B | $2.7B |
| MEDP Dec | $861.0M | $925.9M | $1.1B | $1.5B | $1.9B | $2.1B | $2.5B |
| NTRA Dec | $302.3M | $391.0M | $625.5M | $820.2M | $1.1B | $1.7B | $2.3B |
| RVTY Dec | $2.9B | $3.8B | $3.8B | $3.3B | $2.8B | $2.8B | $2.9B |
| BKD Dec | $4.1B | $3.5B | $2.8B | $2.8B | $3.0B | $3.1B | $3.2B |
| CHE Dec | $1.9B | $2.1B | $2.1B | $2.1B | $2.3B | $2.4B | $2.5B |
| RPRX Dec | $1.8B | $2.1B | $2.3B | $2.2B | $2.4B | $2.3B | $2.4B |
| GMED Dec | $785.4M | $789.0M | $958.1M | $1.0B | $1.6B | $2.5B | $2.9B |
| QDEL Dec | - | $1.7B | $1.7B | $3.3B | $3.0B | $2.8B | $2.7B |
| Peer median | $1.9B | $1.9B | $2.1B | $2.2B | $2.4B | $2.5B | $2.7B |
Sales growth, FY2019 to FY2025
Revenue against the fiscal year before.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| HIMS Dec | - | +80.2% | +82.8% | +93.8% | +65.5% | +69.3% | +59.0% |
| NVST Dec | −3.3% | −15.6% | +30.1% | +2.4% | −0.1% | −2.2% | +8.3% |
| MEDP Dec | +22.2% | +7.5% | +23.4% | +27.8% | +29.2% | +11.8% | +20.0% |
| NTRA Dec | +17.3% | +29.3% | +60.0% | +31.1% | +32.0% | +56.7% | +35.9% |
| RVTY Dec | +3.8% | +31.2% | +43.7% | −13.5% | −16.9% | +0.2% | +3.7% |
| BKD Dec | −10.5% | −12.7% | −22.1% | +2.4% | +6.7% | +3.6% | +2.2% |
| CHE Dec | +7.0% | +4.2% | −5.5% | −4.7% | +9.4% | +7.4% | +4.1% |
| RPRX Dec | +1.1% | +17.0% | +7.9% | −2.3% | +5.2% | −3.9% | +5.1% |
| GMED Dec | +10.2% | +0.5% | +21.4% | +6.8% | +53.3% | +60.6% | +16.7% |
| QDEL Dec | - | - | +2.2% | +92.3% | −8.2% | −7.2% | −1.9% |
| Peer median | +5.4% | +5.9% | +21.4% | +2.4% | +6.7% | +3.6% | +5.1% |
Gross margin, FY2019 to FY2025
Gross profit / revenue.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| HIMS Dec | 54.0% | 73.6% | 75.2% | 77.6% | 82.0% | 79.5% | 73.8% |
| NVST Dec | 59.1% | 54.7% | 56.9% | 57.4% | 56.1% | 54.7% | 54.7% |
| MEDP Dec | - | - | - | - | - | - | - |
| NTRA Dec | - | - | - | - | - | - | - |
| RVTY Dec | 48.4% | 55.8% | 63.6% | 60.1% | - | - | - |
| BKD Dec | 21.6% | 22.5% | 18.2% | 21.0% | 24.8% | 25.6% | 26.2% |
| CHE Dec | - | - | - | - | - | - | - |
| RPRX Dec | - | - | - | - | - | - | - |
| GMED Dec | 77.1% | 72.4% | 75.0% | 74.2% | 65.1% | - | - |
| QDEL Dec | - | - | - | - | - | - | - |
| Peer median | 53.7% | 55.2% | 60.2% | 58.7% | 56.1% | - | - |
Operating margin, FY2019 to FY2025
Operating income / revenue.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| HIMS Dec | −90.1% | −10.2% | −42.3% | −13.0% | −3.4% | 4.2% | 4.5% |
| NVST Dec | 10.3% | 2.3% | 12.2% | 12.4% | 1.2% | −41.4% | 7.9% |
| MEDP Dec | 14.8% | 18.0% | 17.4% | 19.1% | 17.9% | 21.2% | 21.1% |
| NTRA Dec | −38.5% | −55.3% | −74.8% | −66.0% | −41.2% | −13.1% | −13.4% |
| RVTY Dec | 12.6% | 22.9% | 32.9% | 22.4% | 10.9% | 12.6% | 12.5% |
| BKD Dec | −1.1% | −2.8% | −7.9% | −1.5% | 0.6% | 1.5% | 0.4% |
| CHE Dec | 13.3% | 18.7% | 16.0% | 16.1% | 15.0% | 15.1% | 13.4% |
| RPRX Dec | 144.6% | 75.2% | 62.5% | 13.7% | 63.4% | 57.1% | 65.6% |
| GMED Dec | 21.9% | 14.1% | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% |
| QDEL Dec | - | 63.8% | 53.3% | 25.8% | 4.6% | −70.5% | −33.7% |
| Peer median | 12.9% | 18.0% | 17.4% | 16.1% | 8.5% | 6.6% | 12.5% |
Net margin, FY2019 to FY2025
Net income / revenue.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| HIMS Dec | −87.3% | −12.2% | −39.6% | −12.5% | −2.7% | 8.5% | 5.5% |
| NVST Dec | 9.5% | 1.7% | 13.6% | 9.5% | −3.9% | −44.6% | 1.7% |
| MEDP Dec | 11.7% | 15.7% | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
| NTRA Dec | −41.3% | −58.8% | −75.4% | −66.8% | −40.2% | −11.2% | −9.0% |
| RVTY Dec | 7.9% | 19.2% | 24.6% | 17.2% | 25.2% | 9.8% | 8.4% |
| BKD Dec | −6.6% | 2.3% | −3.6% | −8.4% | −6.3% | −6.5% | −8.2% |
| CHE Dec | 11.3% | 15.4% | 12.6% | 11.7% | 12.0% | 12.4% | 10.5% |
| RPRX Dec | 129.4% | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
| GMED Dec | 19.8% | 13.0% | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
| QDEL Dec | - | 48.8% | 41.5% | 16.8% | −0.3% | −73.7% | −41.5% |
| Peer median | 10.4% | 15.4% | 15.6% | 11.7% | 7.8% | 4.1% | 8.4% |
Free cash flow, FY2019 to FY2025
Cash from operations minus capital spending.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| HIMS Dec | - | - | - | −$33.7M | $47.0M | $198.3M | $57.4M |
| NVST Dec | $319.7M | $236.2M | $306.9M | $107.0M | $217.5M | $302.7M | $230.4M |
| MEDP Dec | $184.0M | $227.3M | $235.1M | $351.2M | $396.7M | $572.3M | $681.9M |
| NTRA Dec | −$68.4M | −$202.1M | −$376.3M | −$479.2M | −$286.2M | $69.2M | $109.1M |
| RVTY Dec | $287.1M | $828.5M | $1.3B | $594.2M | $9.9M | $541.7M | $509.4M |
| BKD Dec | −$87.7M | $19.8M | −$271.3M | −$193.6M | −$70.3M | −$35.1M | $16.5M |
| CHE Dec | $248.2M | $430.5M | $249.9M | $252.6M | $273.4M | $368.0M | $325.5M |
| RPRX Dec | - | - | - | - | - | - | - |
| GMED Dec | $101.2M | $135.1M | $219.4M | $104.4M | $165.2M | $405.2M | $588.8M |
| QDEL Dec | - | $564.8M | $513.1M | $744.4M | $70.9M | −$112.1M | −$83.0M |
| Peer median | $184.0M | $231.8M | $242.5M | $179.8M | $118.1M | $335.3M | $277.9M |
FCF margin, FY2019 to FY2025
Free cash flow / revenue.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| HIMS Dec | - | - | - | −6.4% | 5.4% | 13.4% | 2.4% |
| NVST Dec | 14.0% | 12.2% | 12.2% | 4.2% | 8.5% | 12.1% | 8.5% |
| MEDP Dec | 21.4% | 24.6% | 20.6% | 24.1% | 21.0% | 27.1% | 26.9% |
| NTRA Dec | −22.6% | −51.7% | −60.2% | −58.4% | −26.4% | 4.1% | 4.7% |
| RVTY Dec | 10.0% | 21.9% | 34.6% | 17.9% | 0.4% | 19.7% | 17.8% |
| BKD Dec | −2.2% | 0.6% | −9.8% | −6.9% | −2.3% | −1.1% | 0.5% |
| CHE Dec | 12.8% | 20.7% | 11.7% | 11.8% | 12.1% | 15.1% | 12.9% |
| RPRX Dec | - | - | - | - | - | - | - |
| GMED Dec | 12.9% | 17.1% | 22.9% | 10.2% | 10.5% | 16.1% | 20.0% |
| QDEL Dec | - | 34.0% | 30.2% | 22.8% | 2.4% | −4.0% | −3.0% |
| Peer median | 12.8% | 18.9% | 16.4% | 11.0% | 5.4% | 13.6% | 10.7% |
Return on equity, FY2019 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| HIMS Dec | n/m | n/m | −32.2% | −21.1% | −6.8% | 26.4% | 23.7% |
| NVST Dec | 6.1% | 0.9% | 8.4% | 5.8% | −2.4% | −38.1% | 1.5% |
| MEDP Dec | 13.8% | 18.0% | 19.1% | 63.5% | 50.6% | 49.0% | 98.3% |
| NTRA Dec | −44.8% | −47.2% | −72.2% | −77.6% | −56.8% | −15.9% | −12.2% |
| RVTY Dec | 8.1% | 19.5% | 13.2% | 7.7% | 8.8% | 3.5% | 3.3% |
| BKD Dec | −38.5% | 10.2% | −14.2% | −40.9% | −46.8% | −95.0% | n/m |
| CHE Dec | 30.3% | 35.4% | 43.1% | 31.3% | 24.6% | 27.0% | 27.1% |
| RPRX Dec | 38.2% | 9.9% | 6.0% | 0.4% | 11.3% | 8.3% | 7.9% |
| GMED Dec | 11.1% | 6.8% | 8.6% | 10.3% | 3.1% | 2.5% | 11.8% |
| QDEL Dec | - | 60.8% | 36.5% | 11.1% | −0.2% | −68.8% | −58.9% |
| Peer median | 9.6% | 10.2% | 8.6% | 7.7% | 3.1% | 2.5% | 5.6% |
Debt / equity, FY2019 to FY2025
Total debt / shareholders' equity at the year end.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| HIMS Dec | n/m | n/m | - | - | - | - | - |
| NVST Dec | 0.38 | 0.72 | 0.43 | 0.45 | 0.39 | 0.51 | 0.47 |
| MEDP Dec | 0.00 | - | 0.00 | 0.13 | 0.00 | - | - |
| NTRA Dec | 0.44 | 0.52 | 0.51 | 0.51 | 0.47 | 0.07 | 0.05 |
| RVTY Dec | 0.74 | 0.53 | 0.70 | 0.60 | 0.50 | 0.41 | 0.44 |
| BKD Dec | 5.11 | 4.89 | 5.51 | 6.61 | 9.16 | 19.12 | n/m |
| CHE Dec | 0.12 | - | 0.30 | 0.12 | - | - | - |
| RPRX Dec | 1.02 | 0.59 | 0.69 | 0.75 | 0.61 | 0.74 | 0.92 |
| GMED Dec | - | - | - | - | - | - | - |
| QDEL Dec | - | - | 0.00 | 0.54 | 0.48 | 0.83 | 1.40 |
| Peer median | 0.44 | 0.59 | 0.47 | 0.52 | 0.48 | 0.63 | 0.47 |
EPS (diluted), FY2019 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| HIMS Dec | −$2.07 | −$0.51 | −$0.58 | −$0.32 | −$0.11 | $0.53 | $0.51 |
| NVST Dec | $1.60 | $0.20 | $1.92 | $1.37 | −$0.60 | −$6.50 | $0.28 |
| MEDP Dec | $2.67 | $3.84 | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
| NTRA Dec | −$1.79 | −$2.84 | −$5.21 | −$5.57 | −$3.78 | −$1.53 | −$1.52 |
| RVTY Dec | $2.04 | $6.49 | $8.08 | $4.50 | $5.55 | $2.20 | $2.07 |
| BKD Dec | −$1.44 | $0.44 | −$0.54 | −$1.25 | −$0.84 | −$0.89 | −$1.12 |
| CHE Dec | $13.31 | $19.48 | $16.85 | $16.53 | $17.93 | $19.89 | $18.34 |
| RPRX Dec | - | $1.32 | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
| GMED Dec | $1.52 | $1.01 | $1.44 | $1.85 | $1.07 | $0.75 | $3.92 |
| QDEL Dec | - | $18.60 | $16.43 | $9.56 | −$0.15 | −$30.54 | −$16.69 |
| Peer median | $1.60 | $1.32 | $1.92 | $1.85 | $1.07 | $0.75 | $1.78 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out HIMS and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: HIMS's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HIMS/export.csv") into a cell.